As a result, TC-treated MSCs stimulate CD8 T-cell activation efficiently, and elicit potent anti-tumoral responses against the EG.7 T-cell lymphoma in the context of prophylactic vaccination. The gene discussed is CD8A; the disease is T-cell non-Hodgkin lymphoma.